A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
Who is this study for? Patients with Solid Tumors
What treatments are being studied? MRTX1719
Status: Recruiting
Location: See all (24) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue.
• Unresectable or metastatic disease.
• Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.
• Age ≥ 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Adequate organ function.
Locations
United States
Arizona
Mayo Clinic
RECRUITING
Phoenix
Colorado
Sarah Cannon Research Institute (SCRI) - HealthONE Location
RECRUITING
Denver
Rocky Mountain Cancer Centers, LLP - Oncology
RECRUITING
Lone Tree
Florida
Mayo Clinic
RECRUITING
Jacksonville
Sarah Cannon Research Institute at Florida Cancer Specialists
RECRUITING
Orlando
Illinois
Local Institution - 124
WITHDRAWN
Chicago
Massachusetts
Dana-Farber Cancer Institute
RECRUITING
Brookline
Michigan
Cancer and Hematology Centers of Western Michigan
RECRUITING
Norton Shores
Minnesota
Mayo Clinic
RECRUITING
Rochester
North Carolina
University of North Carolina
RECRUITING
Chapel Hill
New Jersey
Rutgers Cancer Institute of New Jersey
RECRUITING
New Brunswick
New York
David H Koch, Memorial Sloan Kettering Cancer Center
RECRUITING
New York
New york cancer and blood specialists - Oncology
RECRUITING
Port Jefferson Station
New york cancer and blood specialists - Oncology
RECRUITING
Port Jefferson Station
Tennessee
Vanderbilt - Ingram Cancer Center
RECRUITING
Nashville
Texas
Ut Southwestern
RECRUITING
Dallas
Texas Oncology - DFW
RECRUITING
Fort Worth
Local Institution - 108
COMPLETED
Houston
MDACC
RECRUITING
Houston
South Texas Accelerated Research Therapeutics
RECRUITING
San Antonio
Texas Oncology, P.A. - Oncology
RECRUITING
Tyler
Virginia
Virginia Cancer Specialists, PC
RECRUITING
Fairfax
Washington
Local Institution - 134
WITHDRAWN
Seattle
Wisconsin
Medical College of Wisconsin - Froedtert Hospital
RECRUITING
Milwaukee
Contact Information
Primary
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain the NCT# and Site #.
Time Frame
Start Date: 2022-06-09
Estimated Completion Date: 2026-04-30
Participants
Target number of participants: 320
Treatments
Experimental: Phase 1/1B
Dose Escalation/Evaluation
Experimental: Phase 1b Sub-Study
MRTX1719 in combination with standard of care therapy in selected solid tumor malignancies with MTAP homozygous deletion
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb